Taken together, these mechanisms may contribute to reduced CD38-mediated adenosine production, an improved host anti-tumor immune response, and the observed synergy between PD-1 blockade and a CD38-targeting antibody in the murine colon cancer model. The gene discussed is PDCD1; the disease is colonic neoplasm.